Compare Sanofi SA (SNY) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs SoundHound AI Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while SoundHound AI Inc trades at $6.54 (market cap $2.75B). The key difference: Sanofi SA is far larger — about 38.1× SoundHound AI Inc's market cap, and Sanofi SA pays a 5.5% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| SNY | SOUN | |
|---|---|---|
Market Cap | $104.83B | $2.75B |
Sector | Health | Technology |
52-Week High | $52.34 | $21.40 |
52-Week Low | $41.33 | $5.90 |
Enterprise Value | $121.32B | $2.54B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SoundHound AI (SOUN) trades at $6.31, down 37% year-to-date amid concerns over persistent losses and cash burn despite 52% revenue growth in 2025. The stock shows a bearish technical trend with neutral oscillators, while fundamentals reveal a negative net income margin of -91.84% and high valuation multiples. Recent positive developments include being named a Leader in Gartner's Magic Quadrant for Conversational AI Platforms (GlobeNewsWire, July 13, 2026) and beating EPS estimates in three consecutive quarters.
The outlook remains speculative with significant upside potential based on a $13.00 analyst consensus price target, but high execution risks and cash burn pose threats. Investment opportunity hinges on the company's ability to monetize its AI platform expansion and achieve profitability, while risks include competitive pressures and reliance on financing to cover operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
